Metabotropic glutamate receptor 5 blockade attenuates pathological cardiac remodelling in pulmonary arterial hypertension
- 8 February 2022
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 49 (5) , 558-566
Abstract
Pulmonary arterial hypertension (PAH) is characterized by cardiac remodelling. Glutaminolysis plays a crucial role in PAH‐induced remodelling. The metabotropic glutamate receptor 5 (mGluR5) may mediate this process. This study investigated whether or not the blockade of mGluR5 may attenuate PAH‐induced pathological cardiac remodelling. Pulmonary arterial hypertension was induced by intraperitoneally injecting male Sprague‐Dawley (SD) rats with 60 mg/kg of monocrotaline (MCT). 3‐((2‐Methyl‐4‐thiazolyl)ethynyl)pyridine (MTEP) (10 mg/kg intraperitoneally) was used as a therapeutic intervention to block mGluR5. Cardiac functions were assessed with right heart catheterization and electrocardiography. Alterations in protein expressions and inflammatory markers were investigated using western blot and enzyme‐linked immunosorbent assay (ELISA), respectively. Increased right ventricular systolic pressure (RSVP), elevated protein expressions of mGluR5, collagen types I and III and cartilage intermediate layer protein 1 (CILP1), enhanced phosphorylation of phosphatidylinositol 3‐kinase (PI3K), AKT and p38 mitogen‐activated protein kinase (P38MAPK), increased angiopoietin 2 (Ang 2) and vascular endothelial growth factor‐α (VEGF) protein expressions and elevated serum levels of interleukin 6 (IL‐6) and tumour necrotic factor α (TNF‐α) were observed in MCT‐induced PAH rats. MTEP improved hemodynamics and right ventricular hypertrophy. MTEP also attenuated MCT‐induced elevations in the protein expressions of mGluR5, collagen types I and III, CILP1, Ang 2 and VEGF and decreased PI3K, AKT and P38MAPK phosphorylations and inflammatory cytokine levels. Metabotropic glutamate receptor 5 blockade using MTEP ameliorates PAH‐induced pathological right cardiac remodelling via inhibiting the signalling cascade involving PI3K/AKT, P38MAPK, Ang 2 and VEGF.Keywords
This publication has 53 references indexed in Scilit:
- Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic ImplicationsInternational Journal of Biological Sciences, 2013
- Involvement of metabotropic glutamate receptor 5, AKT/PI3K Signaling and NF-κB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytesJournal of Neuroinflammation, 2012
- Overexpression of angiopoietin-2 impairs myocardial angiogenesis and exacerbates cardiac fibrosis in the diabetic db/db mouse modelAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Inflammation, immunological reaction and role of infection in pulmonary hypertensionClinical Microbiology and Infection, 2011
- Metabotropic Glutamate Receptors: Physiology, Pharmacology, and DiseaseAnnual Review of Pharmacology and Toxicology, 2010
- Impaired Vasoconstriction and Nitric Oxide-Mediated Relaxation in Pulmonary Arteries of Hypoxia- and Monocrotaline-Induced Pulmonary Hypertensive RatsThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Inhibition of p38 MAPK Suppresses Inflammatory Cytokine Induction by Etoposide, 5-Fluorouracil, and Doxorubicin without Affecting Tumoricidal ActivityPLOS ONE, 2008
- AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine LossNeuron, 2006
- Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failureJournal of Clinical Investigation, 2005
- Activation and signaling of the p38 MAP kinase pathwayCell Research, 2005